Allspring Global Investments Holdings LLC Increases Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Allspring Global Investments Holdings LLC lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 645.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,616 shares of the biotechnology company’s stock after buying an additional 42,091 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Ironwood Pharmaceuticals were worth $556,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Walleye Capital LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the third quarter worth about $1,608,000. Illinois Municipal Retirement Fund bought a new position in shares of Ironwood Pharmaceuticals in the third quarter worth approximately $743,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Ironwood Pharmaceuticals in the third quarter worth approximately $22,903,000. Vanguard Group Inc. increased its position in shares of Ironwood Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 14,895,700 shares of the biotechnology company’s stock worth $143,446,000 after purchasing an additional 49,160 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in shares of Ironwood Pharmaceuticals by 95.8% in the third quarter. Quantbot Technologies LP now owns 69,500 shares of the biotechnology company’s stock worth $669,000 after purchasing an additional 34,000 shares during the last quarter.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $8.08 on Friday. Ironwood Pharmaceuticals, Inc. has a one year low of $7.53 and a one year high of $15.70. The firm’s 50 day simple moving average is $9.64 and its two-hundred day simple moving average is $10.66. The stock has a market capitalization of $1.26 billion, a P/E ratio of -1.24 and a beta of 0.55.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CMO Michael Shetzline sold 38,618 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $588,538.32. Following the transaction, the chief marketing officer now directly owns 340,484 shares in the company, valued at $5,188,976.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Ironwood Pharmaceuticals news, SVP Andrew Davis sold 9,846 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the transaction, the senior vice president now directly owns 208,324 shares in the company, valued at $3,174,857.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Michael Shetzline sold 38,618 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $15.24, for a total transaction of $588,538.32. Following the completion of the transaction, the chief marketing officer now owns 340,484 shares in the company, valued at approximately $5,188,976.16. The disclosure for this sale can be found here. Insiders have sold 273,008 shares of company stock worth $4,160,642 over the last ninety days. Insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on IRWD shares. Piper Sandler upped their price objective on shares of Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Craig Hallum started coverage on shares of Ironwood Pharmaceuticals in a research report on Wednesday, January 17th. They issued a “buy” rating and a $21.00 price objective on the stock. Wells Fargo & Company decreased their price objective on shares of Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, March 1st. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.80.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.